tetano
Editor, Senior Moderator
Drug Discov Today
. 2021 Apr 15;S1359-6446(21)00192-6.
doi: 10.1016/j.drudis.2021.04.006. Online ahead of print.
The fight against COVID-19: striking a balance in the renin-angiotensin system
Alexis Q Dean[SUP] 1 [/SUP], William P Bozza[SUP] 1 [/SUP], Julianne D Twomey[SUP] 1 [/SUP], Shen Luo[SUP] 1 [/SUP], Ancy Nalli[SUP] 1 [/SUP], Baolin Zhang[SUP] 2 [/SUP]
Affiliations
Abstract
The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by interacting with membrane-bound angiotensin-converting enzyme 2 (ACE2), a vital element in the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and cardiovascular functions. We herein evaluate existing evidence for the molecular alterations within the RAS pathway (e.g., ACE2 and angiotensin II) during SARS-CoV-2 infection and subsequent Coronavirus 2019 (COVID-19). This includes reports regarding potential effect of RAS blockade (e.g., ACE inhibitors and angiotensin II receptor blockers) on ACE2 expression and clinical outcomes in patients with co-morbidities commonly treated with these agents. The collective evidence suggests a dual role for ACE2 in COVID-19, depending on the stage of infection and the coexisting diseases in individual patients. This information is further discussed with respect to potential therapeutic strategies targeting RAS for COVID-19 treatment.
Keywords: COVID-19; RAS blockade; SARS-CoV-2; angiotensin II (Ang II); angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system (RAS).
. 2021 Apr 15;S1359-6446(21)00192-6.
doi: 10.1016/j.drudis.2021.04.006. Online ahead of print.
The fight against COVID-19: striking a balance in the renin-angiotensin system
Alexis Q Dean[SUP] 1 [/SUP], William P Bozza[SUP] 1 [/SUP], Julianne D Twomey[SUP] 1 [/SUP], Shen Luo[SUP] 1 [/SUP], Ancy Nalli[SUP] 1 [/SUP], Baolin Zhang[SUP] 2 [/SUP]
Affiliations
- PMID: 33865979
- DOI: 10.1016/j.drudis.2021.04.006
Abstract
The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters host cells by interacting with membrane-bound angiotensin-converting enzyme 2 (ACE2), a vital element in the renin-angiotensin system (RAS), which regulates blood pressure, fluid balance, and cardiovascular functions. We herein evaluate existing evidence for the molecular alterations within the RAS pathway (e.g., ACE2 and angiotensin II) during SARS-CoV-2 infection and subsequent Coronavirus 2019 (COVID-19). This includes reports regarding potential effect of RAS blockade (e.g., ACE inhibitors and angiotensin II receptor blockers) on ACE2 expression and clinical outcomes in patients with co-morbidities commonly treated with these agents. The collective evidence suggests a dual role for ACE2 in COVID-19, depending on the stage of infection and the coexisting diseases in individual patients. This information is further discussed with respect to potential therapeutic strategies targeting RAS for COVID-19 treatment.
Keywords: COVID-19; RAS blockade; SARS-CoV-2; angiotensin II (Ang II); angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system (RAS).